Potential of Netrin-1 as a diagnostic biomarker for ACS

Potential of Netrin-1 as a diagnostic biomarker for ACS

2020.06.29

Netrin-1 is a recently discovered diagnostic biomarker that indicates atherosclerosis, angiogenesis and ischaemia-reperfusion damage; however, to date there are no human studies about its role in...


Smoking associated with higher severity of coronary lesions in young and middle-aged women

Smoking associated with higher severity of coronary lesions in young and middle-aged women

2020.06.22

Smoking is significantly associated with an increased risk of extensive and severe coronary lesions among young and middle-aged female patients with acute coronary syndrome (ACS), according to data...


Lower adherence to antiplatelet therapy linked to smoking status and pre-existing CV disease

Lower adherence to antiplatelet therapy linked to smoking status and pre-existing CV disease

2020.06.15

In patients who have undergone recent percutaneous coronary intervention (PCI), poor adherence to antiplatelet agents can increase the risk of stent thrombosis and death. A group of researchers...


Ticagrelor linked to low bleeding and CV events in NSTEMI patients

Ticagrelor linked to low bleeding and CV events in NSTEMI patients

2020.06.08

In a phase IV, single-arm study of Taiwanese patients with non ST-segment elevation myocardial infarction (NSTEMI), ticagrelor for up to 1 year was associated with a low rate of major bleeding events...


Diabetic status linked to higher mortality in elderly ACS patients undergoing PCI: ELDERLY ACS 2 trial

Diabetic status linked to higher mortality in elderly ACS patients undergoing PCI: ELDERLY ACS 2 trial

2020.06.01

Among elderly patients with acute coronary syndrome (ACS), diabetic status was associated with higher rates of comorbidities, more severe cardiovascular (CV) risk profile and major bleeding...


Ticagrelor monotherapy vs ticagrelor plus aspirin in patients with diabetes mellitus undergoing PCI: the TWILIGHT study

Ticagrelor monotherapy vs ticagrelor plus aspirin in patients with diabetes mellitus undergoing PCI: the TWILIGHT study

2020.05.29

Current standard of care for prevention of thrombotic complications in patients undergoing percutaneous coronary intervention (PCI) is dual antiplatelet therapy (DAPT) with ticagrelor and aspirin,...


Ticagrelor monotherapy vs ticagrelor plus aspirin after complex PCI: the TWILIGHT-COMPLEX analysis

Ticagrelor monotherapy vs ticagrelor plus aspirin after complex PCI: the TWILIGHT-COMPLEX analysis

2020.05.25

Ticagrelor monotherapy has been shown to attenuate bleeding complications without increasing ischaemic risk in patients undergoing complex percutaneous coronary intervention (PCI). A recent study has...


Ticagrelor monotherapy benefits post-PCI in ACS patients: TICO trial

Ticagrelor monotherapy benefits post-PCI in ACS patients: TICO trial

2020.05.22

In patients who underwent percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), ticagrelor monotherapy after 3 months of dual antiplatelet therapy (DAPT) was superior at...


FDA approves dapagliflozin for the treatment of HFrEF

FDA approves dapagliflozin for the treatment of HFrEF

2020.05.18

Earlier this month, the US Food and Drug Administration (FDA) approved dapagliflozin for the treatment of heart failure with reduced ejection fraction (HFrEF) in adults with and without type 2...


Baseline renal dysfunction linked to higher mortality in elderly ACS patients undergoing PCI

Baseline renal dysfunction linked to higher mortality in elderly ACS patients undergoing PCI

2020.05.11

Chronic kidney disease is prevalent in patients admitted with acute coronary syndrome (ACS), and becomes more common with increasing age. In this study, researchers sought to assess the impact...